Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38α MAP kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 8, 2008, Pages 2739-2744

  Wrobleski, Stephen T ^a   Lin, Shuqun ^a   Hynes Jr , John ^a   Wu, Hong ^a   Pitt, Sidney ^a   Shen, Ding Ren ^a   Zhang, Rosemary ^a   Gillooly, Kathleen M ^a   Shuster, David J ^a   McIntyre, Kim W ^a   Doweyko, Arthur M ^a   Kish, Kevin F ^a   Tredup, Jeffrey A ^a   Duke, Gerald J ^a   Sack, John S ^a   McKinnon, Murray ^a   Dodd, John ^a   Barrish, Joel C ^a   Schieven, Gary L ^a   Leftheris, Katerina ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

IL 1; Inflammation; Kinase; p38; Pyrrolotriazines; TNF

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMIDES; ANIMALS; CRYSTALLOGRAPHY, X-RAY; FEMALE; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41849106872     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.02.067     Document Type: Article

References (34)

1. Kavanaugh A. Adv. Ther. 23 (2006) 208
2. Fleischmann R. Expert Rev. Clin. Immunol. 2 (2006) 331
3. Grunke M., and Kalden J.R. Expert Rev. Clin. Immunol. 1 (2005) 313
4. Saleem B., Mackie S., and Emery P. Expert Rev. Clin. Immunol. 2 (2006) 193
5. Cottone M., Mocciaro F., and Modesto I. Expert Opin. Biol. Ther. 6 (2006) 401
6. Papadakis K.A. Expert Rev. Clin. Immunol. 2 (2006) 11
7. Mease P.J. Expert Opin. Biol. Ther. 5 (2005) 1491
8. Lee S.J., and Kavanaugh A. Therapy 2 (2005) 13
9. Wagner G., and Laufer S. Med. Res. Rev. 26 (2006) 1
10. Adams J.L., Badger A.M., Kumar S., and Lee J.C. Prog. Med. Chem. 38 (2001) 1
11. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., and Heyes J.R. Nature 372 (1994) 739
12. Hale K.K., Trollinger D., Rihanek M., and Manthey C.L. J. Immunol. 162 (1999) 4246
13. Allen M., Svensson L., Roach M., Hambor J., McNeish J., and Gabel C.A. J. Exp. Med. 191 (2000) 859
14. Fearns C., Kline L., Gram H., Di Padova F., Zurini M., Han J., and Ulevitch R.J. J. Leukocyte Biol. 67 (2000) 705
15. For reviews of this area see:. Hynes Jr. J., and Leftheris K. Curr. Top. Med. Chem. 5 (2005) 967
16. Goldstein D.M., and Gabriel T. Curr. Top. Med. Chem. 5 (2005) 1017
17. Diller D.J., Lin T.H., and Metzger A. Curr. Top. Med. Chem. 5 (2005) 953
18. Dominguez C., Powers D.A., and Tamayo N. Curr. Opin. Drug Disc. Dev. 8 (2005) 421
19. Leftheris K., Ahmed G., Chan R., Dyckman A.J., Hussain Z., Ho K., Hynes Jr. J., Letourneau J., Li W., Lin S., Metzger A., Moriarty K.J., Riviello C., Shimshock Y., Wen J., Wityak J., Wrobleski S.T., Wu H., Wu J., Desai M., Gillooly K.M., Lin T.H., Loo D., McIntyre K.W., Pitt S., Shen D.R., Shuster D.J., Zhang R., Diller D., Doweyko A., Sack J., Baldwin J., Barrish J., Dodd J., Henderson I., Kanner S., Schieven G.L., and Webb M. J. Med. Chem. 47 (2004) 6283
20. Liu C., Wrobleski S.T., Lin J., Ahmed G., Metzger A., Wityak J., Gillooly K.M., Shuster D.J., McIntyre K.W., Pitt S., Shen D.R., Zhang R.F., Zhang H., Doweyko A.M., Diller D., Henderson I., Barrish J.C., Dodd J.H., Schieven G.L., and Leftheris K. J. Med. Chem. 48 (2005) 6261
21. Hynes Jr. J., Dyckman A.J., Lin S., Wrobleski S.T., Wu H., Gillooly K.M., Kanner S.B., Lonial H., Loo D., McIntyre K.W., Pitt S., Shen D.R., Shuster D.J., Yang X., Zhang R., Behnia K., Zhang H., Marathe P.H., Doweyko A.M., Tokarski J.T., Sack J.S., Pokross M., Kiefer S.E., Newitt J.A., Barrish J.C., Dodd J., Schieven G.L., and Leftheris K. J. Med. Chem. 51 (2008) 4
22. Hunt J.T., Mitt T., Borzilleri R., Gullo-Brown J., Fargnoli J., Fink B., Han W.-C., Mortillo S., Vite G., Wautlet B., Wong T., Yu C., Zheng X., and Bhide R. J. Med. Chem. 47 (2004) 4054
23. Fink B.E., Vite G.D., Mastalerz H., Kadow J.F., Kim S.-H., Leavitt K.J., Du K., Crews D., Mitt T., Wong T.W., Hunt J.T., Vyas D.M., and Tokarski J.S. Bioorg. Med. Chem. Lett. 15 (2005) 4774
24. Borzilleri R.M., Zheng X., Qian L., Ellis C., Cai Z.-W., Wautlet B.S., Mortillo S., Jeyaseelan R., Kukral D.W., Fura A., Kamath A., Vyas V., Tokarski J.S., Barrish J.C., Hunt J.T., Lombardo L.J., Fargnoli J., and Bhide R.S. J. Med. Chem. 48 (2005) 3991
25. Cumming J.G., McKenzie C.L., Bowden S.G., Campbell D., Masters D.J., Breed J., and Jewsbury P. Bioorg. Med. Chem. Lett. 14 (2004) 5389 and references therein
26. Kamijo S., Kanazawa C., and Yamamoto Y. J. Am. Chem. Soc. 127 (2005) 9260
27. Hynes Jr. J., Doubleday W.W., Dyckman A.J., Godfrey Jr. J.D., Grosso J.A., Kiau S., and Leftheris K. J. Org. Chem. 69 (2004) 1368
28. 50 values for test compounds (concentration of compound that inhibited LPS-stimulated TNF-α production by 50%) were calculated by linear regression analysis.
29. Liverton N.J., Butcher J.W., Claiborne C.F., Claremon D.A., Libby B.E., Nguyen K.T., Pitzenberger S.M., Selnick H.G., Smith G.R., Tebben A., Vacca J.P., Varga S.L., Agarwal L., Dancheck K., Forsyth A.J., Fletcher D.S., Frantz B., Hanlon W.A., Harper C.F., Hofsess S.J., Kostura M., Lin J., Luell S., O'Neill E.A., Orevillo C.J., Pang M., Parsons J., Rolando A., Sahly Y., Visco D.M., and O'Keefe S.J. J. Med. Chem. 42 (1999) 2180
30. Fitzgerald C.E., Patel S.B., Becker J.W., Cameron P.M., Zaller D., Pikounis V.B., O'Keefe S.J., and Scapin G. Nat. Struct. Biol. 10 (2003) 764 Based on Ref. 17b the p38α binding mode from X-ray studies for a p38 inhibitor showing a preference for a (S)-α-methylbenzyl group is depicted below:{A figure is presented}
31. 5-p38α 30 inhibitor complexes grew spontaneously in hanging drop vapor-diffusion trials conducted at 4 °C with drops containing 1 μL of concentrated protein-inhibitor complex mixed with an equal volume of reservoir solution (10% PEG 8000, 200 mM KCl, 100 mM MgOAc, 50 mM sodium cacodylate, pH 6.5). Prior to data collection, the crystals were slowly transferred to a stabilization solution (8% glycerol, 30% PEG 8000, 200 mM KCl, 100 mM MgOAc, 50 mM sodium cacodylate, pH 6.5) and then flash-frozen in liquid nitrogen. Data to 2.4 Å resolution were collected at the IMCA-CAT beamline BM-17 at the Advanced Photon Source, Argonne, IL. On a MarCCD detector, reduced with the programs DENZO and SCALEPACK, (Otwinowski, Z.; Minor, W. Processing X-ray data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.) and refined by program autoBuster (Global Phasing, Ltd, Cambridge, U.K.). The final crystallographic refinement R-factor was 21.2%. The coordinates have been deposited in the Protein Data Bank as entry 3BV2.
32. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N.l., Pav S., and Regan J. Nat. Struct. Biol. 9 (2002) 268
33. Based on Ref. 13, the p38α binding mode for a quinazoline p38 inhibitor based on X-ray crystallography studies is depicted below: {A figure is presented}.
34. Wrobleski S.T., and Doweyko A.M. Curr. Top. Med. Chem. 5 (2005) 1005